D. Global Phase III Trials of Perampanel, a Selective AMPA Receptor Antagonist, as Adjunctive Therapy in Patients with Refractory Partial- Onset Seizures

D. Global Phase III Trials of Perampanel, a Selective AMPA Receptor Antagonist, as Adjunctive Therapy in Patients with Refractory Partial- Onset Seizures

63rd American Academy of Neurology Annual Meeting – Honolulu, Hawaii, USA

– 4/2011

Donar ahora